Mutation detail:
| Mutation site | Y1631C |
| Virus | Human respiratory syncytial virus |
Mutation level  |
Amino acid Level |
| Gene/protein/region type | L |
| Gene ID | 1494467 |
| Country | - |
| Mutation type |
nonsynonymous mutation |
| Genotype/subtype/clade | A |
| Sample |
cell line |
| Variants | - |
| Viral reference sequence | M74568.1 |
| Drug/antibody/vaccine | AZ-27-resistant |
| Transmissibility |
- |
| Transmission mechanism | - |
| Pathogenicity |
- |
| Pathogenicity mechanism | - |
| Immune escape mutation | - |
| Immune escape mechanism | - |
| RT-PCR primers probes | - |
Protein detail:
| Protein name | Polymerase |
| Uniprot protein ID | P28887 |
| Protein length | 2165 amino acids |
| Protein description | The core polymerase in RSV is composed of two proteins, a 250 kDa polymerase subunit (L), which contains the RNA-dependent RNA polymerase, the polyribonucleotidyl transferase (PRNTase, capping), and the methyltransferase enzymatic domains essential for viral transcription and replication, and the 27 kDa phosphoprotein (P) accessory protein. . The L protein caps mRNA by a unique RNA-GDP polyribonucleotidyl transferase activity mapped to conserved region V (CRV). Methylation of the cap at the guanine-N-7 and ribose-2-O positions is catalyzed by a unique dual specificity methyltransferase activity that has been functionally mapped to region VI of the L protein. |
Literature information:
| Pubmed ID | 24777090 |
| Clinical information | No |
| Disease | - |
| Published year | 2014 |
| Journal | Antimicrobial Agents and Chemotherapy |
| Title | Characterization of a Respiratory Syncytial Virus L Protein Inhibitor |
| Author | Choi-Lai Tiong-Yip,Lisa Aschenbrenner,Kenneth D. Johnson,Robert E. McLaughlin,Jun Fan |
| Evidence | Interestingly, Y1631C was the amino acid substitution observed at this site, as opposed to the Y1631H variant observed in the resistant virus. These data suggested that the RSV replicon can be used for compound resistance studies and further implicated Y1 |